JOHN KIRKWOOD to United States
This is a "connection" page, showing publications JOHN KIRKWOOD has written about United States.
Connection Strength
0.211
-
A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017 Aug 01; 3(8):1112-1115.
Score: 0.043
-
IFN-a in the treatment of melanoma. J Immunol. 2012 Oct 15; 189(8):3789-93.
Score: 0.031
-
An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
Score: 0.015
-
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018 05 14; 6(1):35.
Score: 0.011
-
Management strategies of academic pigmented lesion clinic directors in the United States. J Am Acad Dermatol. 2018 Aug; 79(2):367-369.
Score: 0.011
-
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018 Feb; 25(2):356-377.
Score: 0.011
-
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.
Score: 0.011
-
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
Score: 0.008
-
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
Score: 0.008
-
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32.
Score: 0.007
-
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
Score: 0.006
-
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17; 7:45.
Score: 0.006
-
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med. 2008 Dec 23; 6:81.
Score: 0.006
-
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5748-54.
Score: 0.006
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
Score: 0.006
-
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004 Jun 01; 22(11):2101-7.
Score: 0.004
-
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.
Score: 0.004
-
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002 Mar-Apr; 25(2):97-138.
Score: 0.004
-
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
Score: 0.004
-
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
Score: 0.004
-
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 Aug 15; 19(16):3635-48.
Score: 0.004
-
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000 Mar 15; 88(6):1484-91.
Score: 0.003